期刊文献+

恶性腹膜间皮瘤的诊治体会 被引量:5

Diagnosis and Management of Patients with Malignant Peritoneal Mesothelioma
下载PDF
导出
摘要 目的:提高对恶性腹膜间皮瘤的诊断和治疗水平。方法:对我院40年来收治的22例恶性腹膜间皮瘤患者的临床资料结合相关文献进行回顾性分析。结果:22例收治经病理证实的患者,男性9例,女性13例,年龄18~72岁,13例行减瘤手术+腹腔或/和全身化疗,1例行手术减瘤+腹部放疗;4例行剖腹探查+腹腔及全身化疗;1例未手术,仅行腹腔+全身化疗;3例未手术,仅行全身化疗。经治疗后随访中位生存期18.5月,3例存活超过5年。结论:恶性腹膜间皮瘤诊断困难,易误诊,预后差,主要依靠剖腹探查、腹水细胞学、B超引导穿刺活检、腹腔镜活检等方法,治疗主要以手术切除减瘤术结合全身化疗的综合治疗为主要手段。 Objective: To summarize the experience of diagnosis and management of malignant peritoneal mesothelioma. Methods: We reviewed the clinical data from 22 patients with malignant peritoneal mesothelioma who were admitted in our hospital in the past 40 years. Results: All of the diagnosis were proved pathologically, 9 males and 13 females, with a median age of 49,(range 18-72 years). Thirteen cases underwent eytoreduetive surgery and intraperitoneal and/or systematic chemotherapy, 1 ease received eytoreduetive surgery and abdominal regional radiotherapy, 4 eases had laparotnmy exploration and intraperitoneal and/or systematic ehemntherapy, 1 ease reeeived intraperitoneal and systematic ehemotherapy without surgery, and 3 cases only received systematic chemotherapy. The median survival time was 18.5 months, and there were 3 patients who survived over 5 years. Conclusion: The diagnosis of malignant peritoneal mesothelioma is diffieuh, and its prognosis is poor. Diagnostic methods include laparotomy exploration, ascites cytological examination, fine needle biopsy guided by B-US, and biopsy by laparoscope. Surgical cytoreduction combined with chemotherapy is the main management.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2007年第23期1365-1367,共3页 Chinese Journal of Clinical Oncology
关键词 恶性腹膜间皮瘤 诊断 治疗 Malignant peritoneal mesothelioma Diagnosis Therapy
  • 相关文献

参考文献10

  • 1刘复生,刘彤华主编..肿瘤病理学[M],1997:2063.
  • 2Kane AB. Animal models of malignant mesothelioma [J]. Inhal Toxicol, 2006, 18(12): 1001 -1004. 被引量:1
  • 3Robinson BW, Musk AW, Lake RA. Malignant mesothelioma[J]. Lancet, 2005, 366(9483): 397-408. 被引量:1
  • 4Hammar SP. Macroscopic, histologic, histochemical, irnmunohistochemical, and ultrastructural features of mesothelioma[J]. Ultrastruct Pathol, 2006, 30(1): 3-17. 被引量:1
  • 5Sivertsen S, Bemer A, Michael CW, et al, Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions [J], Acta Cytol, 2006, 50(6): 603-607. 被引量:1
  • 6Ordonez NG. Immunohistochernical diagnosis of epithelioid mesothelloma: an update[J]. Arch Pathol Lab Med, 2005, 129(11): 1407- 1414. 被引量:1
  • 7Garcia---Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma [J]. EurJ Surg Oncol, 2006, 32(6): 676-681. 被引量:1
  • 8Sugarbaker PH, Yan TD, Smart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma [J], Eur J Surg Oncol, 2006, 32(6): 686-691. 被引量:1
  • 9Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute [J]. Surg Oncol Clin N Am, 2003, 12(3): 605-621. 被引量:1
  • 10Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hypelthermic perfusion[J]. Ann Surg Oncol, 2006, 13 (2): 229-237. 被引量:1

同被引文献33

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部